SCHEMBL2303383

SCHEMBL2303383

OCc1cc(F)c(OCc2ccccc2)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 5/20 0.48
MAOA P21397 2/20 0.48
MAOB P27338 2/20 0.48
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45
FFAR4 Q5NUL3 1/20 0.45
TSHR P16473 2/20 0.45
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
LMNA P02545 2/20 0.43
SLC6A2 P23975 2/20 0.43
SLC6A3 Q01959 2/20 0.43
HPGD P15428 1/20 0.43
CYP1A2 P05177 1/20 0.43
PTGS1 P23219 1/20 0.43
CYP2C19 P33261 1/20 0.43
PTGS2 P35354 1/20 0.43
HIF1A Q16665 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081406 0.86 CYP4F2 (0.57) KDM1AMAOAMAOBTHRATHRB
SCHEMBL9823890 0.85 KDM1A (0.50) KDM1AMAOAMAOBTHRATHRB
SCHEMBL1055709 0.83 MGAM (0.45) MAOBLMNAHPGDSMN1; SMN2NPC1
SCHEMBL13014915 0.81 THRA (0.52) KDM1AMAOAMAOBTHRATHRB
SCHEMBL25366114 0.80 KDM1A (0.47) KDM1AMAOAMAOBTHRATHRB
SCHEMBL5065124 0.80 KDM1A (0.52) KDM1AMAOAMAOBTHRATHRB
SCHEMBL1017228 0.80 KDM1A (0.54) KDM1AMAOAMAOBTHRATHRB
SCHEMBL12799710 0.80 KDM1A (0.49) KDM1AMAOAMAOBTHRATHRB
SCHEMBL4420078 0.80 LIPE (0.47) TSHRCYP4F2CYP4A11LMNASLC6A2
SCHEMBL1462187 0.79 S1PR5 (0.56) TSHRLMNAHPGDSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2690095-A1 Aryl gpr120 receptor agonists and uses thereof Camabay Therapeutics, Inc. (US) 2014-01-29 EP disclosed
CN-102186825-A Aryl gpr120 receptor agonists and uses thereof METABOLEX INC 2011-09-14 CN disclosed
EP-2350016-A2 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-08-03 EP disclosed
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-08-26 US disclosed
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-08-26 US disclosed
WO-2010048207-A2 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM1A 4076/4885MAOA 2882/4885MAOB 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.